Sapien Biosciences
Sapien Biosciences is a Hyderabad-based joint venture between Apollo Hospitals and Saarum Innovations operating Asia's largest commercial biobank of 200,000 patients, providing companion diagnostics, patient-derived tumor models, and phenotypic drug discovery services to pharma, biotech, and academic clients.
- Company typePrivate
- Founded2012
- HeadquartersHyderabad, India
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Sapien Biosciences does
Sapien Biosciences is a Hyderabad-based joint venture between Apollo Hospitals and Saarum Innovations, founded in 2012, operating Asia's largest commercial tumor tissue biobank with 200,000 unique patients, 2,045,000 samples, and 150 unique diseases covered. The company is structured around an ethically consented, anonymized human sample repository linked to associated clinical, pathological, and diagnostic data, and uses this asset to power a portfolio of translational platforms—OncoBloc (FFPE collections), OncoPrime (patient-derived live cancer cells), MetBlock (EMT-based metastasis model), TruCell (patient/normal cells), and TruScreen (functional drug-efficacy assays)—alongside companion diagnostic products including the myPlatelet combination genetic/functional platelet test, a 43-gene HRR NGS panel for ovarian cancer, and BRCA1/2 testing.
The company's commercial offering spans biobank access, drug-discovery partnerships with global pharmaceutical and biotech firms, in-house and co-developed companion diagnostics, immunohistochemistry and digital pathology services at 40X whole-slide resolution, and immuno-oncology cell assays including 2D/3D spheroid and DC-MLR models. Revenue mechanics combine subscription-style biobank access, licensing/royalty arrangements on diagnostic IP, professional services for collaborative research, and per-test fees for diagnostics such as myPlatelet. Go-to-market is enterprise B2B, distributed through direct sales to pharma/biotech and academic institutions, with Apollo Hospitals functioning as both a strategic JV parent and the primary distribution channel for diagnostic deployment across its hospital network.
Sapien serves three primary customer segments—pharmaceutical and biotechnology companies requiring human samples and patient-derived models for preclinical and translational work, academic and research institutions conducting cancer and life sciences research, and healthcare providers/hospitals implementing personalized medicine diagnostics. The company holds no external venture or private equity funding disclosed in the source material, and is operated by founders Jugnu Jain (CSO), Sreevatsa Natarajan (CEO), and Prithi Rajan (Executive Director) with combined 60+ years of R&D experience.
Sapien Biosciences firmographics
Firmographics- Name
- Sapien Biosciences
- Legal name
- Sapien Biosciences
- Website
- https://sapienbio.co.in
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Sapien Biosciences is a Hyderabad-based joint venture between Apollo Hospitals and Saarum Innovations operating Asia's largest commercial biobank of 200,000 patients, providing companion diagnostics, patient-derived tumor models, and phenotypic drug discovery services to pharma, biotech, and academic clients.
- Ownership category
- akta.pro rank
Sapien Biosciences industry classification
Industry- Product category
- Biobanking & Translational Research Services
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Biobank & Biospecimen Management LIMS (HLACAMAG)
- akta.pro secondary industries
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Cell-Based & Potency Assays (Bioassays) (HLAGADAH), Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF), Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK)
Keywords
Where Sapien Biosciences is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices1 record
Markets served
Sapien Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain
Revenue model
- Biobanking Services: Providing ethically consented human samples with associated medical and diagnostic data to pharmaceutical companies, biotech firms, and academic researchers for drug discovery and biomarker validation.
- Diagnostic Development: Developing and commercializing novel diagnostic tests including companion diagnostics and personalized medicine applications, either in-house or in collaboration with partner institutions.
- Drug Discovery Partnerships: Partnering with global pharmaceutical and biotech companies to study disease epidemiology, validate new diagnostics, identify drug targets, and evaluate new drugs using proprietary biobank resources.
- myPlatelet Test: Commercial sale of proprietary combination genetic and functional platelet function test for cardiology patients undergoing PCI-stent procedures.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
Sapien Biosciences product offering
Product offeringCore offering
Sapien Biosciences operates one of Asia's largest commercial biobanks with 200,000 unique patients, 2,045,000 samples, and 150 unique diseases covered, providing ethically consented, anonymized human tissue samples with associated clinical data. The company offers proprietary translational platforms (OncoBloc FFPE collections, OncoPrime patient-derived live cancer cells, MetBlock metastasis EMT model, TruCell, TruScreen) and companion diagnostic tests (myPLATELET pharmacogenomic platelet test, HRR NGS panel, BRCA1/2 testing) for pharmaceutical companies, biotech firms, academic researchers, and healthcare providers.
Product overview
Sapien Biosciences is a biobank-led companion diagnostics and phenotypic drug discovery company offering a comprehensive portfolio of products and services. The core offering centers on Asia's largest commercial biobank with over 200,000 patients and 2 million+ samples. This biobank powers multiple translational platforms including OncoBloc (FFPE collections), OncoPrime (patient-derived live cancer cells), MetBlock (metastasis EMT model), TruCell (patient/normal cells), and TruScreen (functional assays). The company provides companion diagnostic services including myPLATELET (pharmacogenomic platelet function test), HRR NGS panel testing for PARP inhibitor guidance, and BRCA1/2 testing. Additional services include IHC staining with digital pathology and cell-based immuno-oncology assays for drug efficacy testing.
Differentiator
Problem solved
Functional benefit
Brands
- OncoBloc: Fixed and frozen FFPE sample collections for cancer research.
- OncoPrime
- MetBlock
- TruCell
- TruScreen
- myPLATELET
Products and services
- OncoBloc
- OncoPrime
- MetBlock
- TruCell
- TruScreen
- myPLATELET
- HRR NGS Panel (43-gene)
- Biobank Services
- IHC Staining & Digital Pathology Services
- Cell Assays for Immuno-Oncology
Quantifiable outcome
- Patient-derived models contributing to Phase III clinical development program
- +2 more outcomes
Companies that use Sapien Biosciences
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
Sapien Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature10 records
Sapien Biosciences partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered flagship, core and minor.
- Apollo HospitalsflagshipJoint venture partnership creating a world-class biobank and personalized medicine company. Sapien has exclusive access to the entire Apollo network for biobanking needs. Alliance allows Sapien to front-end Apollo's personalized medicine initiatives, bringing novel cutting-edge diagnostics to Apollo either independently or in collaboration with global institutions.
- Saarum InnovationsflagshipCo-founding partner providing cutting-edge life sciences research expertise. The Saarum team manages Sapien operations with over 60 years of combined global R&D experience in cell and molecular biology and drug and biomarker discovery.
- Aveta BiomicscoreCollaboration on drug development efforts using Sapien's patient-derived models and NAMs. Contribution to Aveta's therapeutic program advancing toward Phase III clinical development, demonstrating meaningful translational insights for cancer patients.
- Boston UniversitycoreCollaboration with Dr. Joglekar's group at Boston University Questrom School of Business to perform cost-benefit analysis of treatment paradigms in PCI-stent patients using Sapien's cardiac database of approximately 800 patients. Research expected to be published and pave way for additional studies.
- FABA-USminorFABA-US Chapter webinar collaboration featuring Sapien's biobank capabilities. Dr. Jugnu Jain presented on human patient samples and clinical data at FABA-US monthly webinar series.
- Dr. PC Rath (Apollo Hospitals)coreLeading cardiologist collaborating with Sapien on cardiac patient database collation and research on anti-platelet therapy optimization for PCI-stent patients.
- Dr. PK Sahoo (Apollo Hospitals)coreCardiologist collaborating on cardiac research and myPlatelet test utilization for personalized anti-platelet therapy in PCI-stent patients.
- SV College of PharmacyminorCollaboration with Dr. A Yerramilli at SV College of Pharmacy for cardiac patient research and data analysis.
- BioNestminorMentioned in context of partnership discussions and industry collaboration for biobanking and life sciences ecosystem development.
- University of HyderabadminorAcademic collaboration for glioma patient-derived 3D cultures research presented at Regional Young Investigator Meeting.
Scale indicators10 records
Recent moves7 records
Expansion highlights5 records
Sapien Biosciences competitors and assessment
Company assessmentRegional players
- MedGenome: India-headquartered genomics and translational research company offering NGS, biomarker, and clinical genomics services. Regional peer with overlapping India-population genetics focus and pharma/biotech diagnostics service offering.
- Strand Life Sciences: India-based genomics, bioinformatics, and clinical diagnostics provider serving hospitals and pharma. Comparable on India footprint and clinical genomics/multi-omics services, partially overlapping with Sapien's HRR NGS panel and diagnostic development work.
Emerging players
- Reprocell (now part of Axol Bioscience): Provider of human cell-based products, iPSC-derived cells, and biobanking services for drug discovery. Overlaps with Sapien's TruCell patient-derived cell platform and drug discovery service line.
Direct peers
- Cureline: Global human biospecimen supplier specializing in oncology and disease-state tissue with annotated clinical data. Comparable to Sapien's translational biobank services for pharma clients.
- Indivumed: Specialized oncology biobank and translational CRO providing fresh-frozen and FFPE tumor tissue with clinical data, directly comparable to Sapien's OncoBloc and OncoPrime offerings.
- Origene Technologies: Commercial provider of human tissue, biofluid, and cell specimens with associated data for research and diagnostic development. Direct peer in the biospecimen catalog business.
- BioIVT: One of the world's largest commercial biospecimen providers offering ethically sourced human samples and associated data to pharma/biotech. Sapien is a direct peer in the commercial biobank/cryobank space but with a narrower oncology and India focus.
Broad incumbents
- Brooks Life Sciences (Brooks Automation): Large established sample storage, biobanking, and life-science services provider with global footprint. Overlaps with Sapien's biobank services but operates at much broader scale and across many therapeutic areas.
- Avantor: Global life science products and services company offering biorepository and biospecimen solutions. A broad incumbent in the lab-services and biospecimen value chain that competes for similar pharma procurement budgets.
- Molecular Diagnostics (MolDx) Labs / Agilent Dako: Incumbent companion diagnostics and IHC/pharmDx providers such as Agilent Dako offering CDx development and IHC assays. Overlaps with Sapien's HRR NGS panel, myPlatelet, and IHC staining services in the precision medicine/CDx value chain.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Sapien Biosciences social profiles
Digital presenceSapien Biosciences compliance and trust
Trust signalCompliance1 record
Sapien Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sapien Biosciences leadership team
Management profileNumber of profiles
Profiles3 records
Sapien Biosciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sapien Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sapien Biosciences
What does Sapien Biosciences do?
Sapien Biosciences operates one of Asia's largest commercial biobanks with 200,000 unique patients, 2,045,000 samples, and 150 unique diseases covered, providing ethically consented, anonymized human tissue samples with associated clinical data. The company offers proprietary translational platforms (OncoBloc FFPE collections, OncoPrime patient-derived live cancer cells, MetBlock metastasis EMT model, TruCell, TruScreen) and companion diagnostic tests (myPLATELET pharmacogenomic platelet test, HRR NGS panel, BRCA1/2 testing) for pharmaceutical companies, biotech firms, academic researchers, and healthcare providers.
Is Sapien Biosciences a public or private company?
Sapien Biosciences is a private company. It is classified as corporate owned and is currently operating.
When was Sapien Biosciences founded?
Sapien Biosciences was founded in 2012. It employs 11 to 50 people.
Where is Sapien Biosciences based?
Sapien Biosciences is headquartered in Hyderabad, India, in the Asia region.
How does Sapien Biosciences make money?
Four revenue lines are on record. Biobanking Services are the primary driver. The others are diagnostic Development, drug Discovery Partnerships and myPlatelet Test.
Who are Sapien Biosciences's main competitors?
Regional players on record are MedGenome and Strand Life Sciences. Reprocell (now part of Axol Bioscience) is listed as an emerging player. Direct peers are Cureline, Indivumed, Origene Technologies and BioIVT. Broad incumbents are Brooks Life Sciences (Brooks Automation), Avantor and Molecular Diagnostics (MolDx) Labs / Agilent Dako.
Does Sapien Biosciences have an API?
No public API is recorded for Sapien Biosciences.
What industry is Sapien Biosciences in?
Sapien Biosciences's product category is Biobanking & Translational Research Services. Its primary akta.pro industry code is HLACAMAG, Biobank & Biospecimen Management LIMS, with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.